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2SUMMARY
Risk of insulin resistance, impaired glycemic control and cardiovascular disease is excessive
in overweight and obese populations. We hypothesised that increasing expression of
glyoxalase 1 (Glo1) – an enzyme that catalyses the metabolism of reactive metabolite and
glycating agent, methylglyoxal – may improve metabolic and vascular health. Dietary
bioactive compounds were screened for Glo1 inducer activity in a functional reporter assay,
hits confirmed in cell culture and an optimised Glo1 inducer formulation evaluated in a
randomised, placebo-controlled crossover clinical trial in 29 overweight and obese subjects.
We found trans-resveratrol (tRES) and hesperetin (HESP), at concentrations achieved
clinically, synergised to increase Glo1 expression. In highly overweight subjects (BMI >27.5
kg/m2), tRES-HESP co-formulation increased expression and activity of Glo1 (+ 27%.
P<0.05), decreased plasma methylglyoxal (-37%, P<0.05) and total body methylglyoxal-
protein glycation (-14%, P<0.01). It decreased fasting and postprandial plasma glucose (-5%,
P<0.01 and – 6%, P<0.03, respectively), increased Oral Glucose Insulin Sensitivity index
(+42 mlmin-1m-2, P<0.02) and improved arterial dilatation ΔFMD/ΔGTND (95%CI 0.13–
2.11). In all subjects, it decreased vascular inflammation marker sICAM-1 (-10%, P<0.01). In
previous clinical evaluations, tRES and HESP individually were ineffective. tRES-HESP co-
formulation could be a suitable treatment for improved metabolic and vascular health in
overweight and obese populations.
Key words: glyoxalase, glycation, methylglyoxal, obesity metabolism, insulin resistance,
glycemic control.
3Increasing overweight and obese populations are driving a global epidemic of type 2 diabetes
and cardiovascular disease in Westernised countries. Glyoxalase 1 (Glo1) was linked to
clinical obesity through association with measures of fat deposition and Glo1 deficiency
identified as a driver of cardiovascular disease in a large integrative genomics study (1; 2). It
is currently unaddressed by therapeutic agents. Experimental studies found overexpression of
Glo1 in mice suppressed inflammation and body weight gain in overfeeding models of
obesity and prevented vascular disease in diabetes – as reviewed (3).
Glo1 is part of the glyoxalase metabolic pathway which consists of two enzymes: Glo1
and glyoxalase 2 and a catalytic amount of reduced glutathione (GSH) in the cytoplasm of
cells (Fig. 1A). The major function of the glyoxalase pathway is detoxification of the reactive
dicarbonyl metabolite, methylglyoxal, converting it to D-lactate. Methylglyoxal is a highly
potent glycating agent of protein which forms the quantitatively major advanced glycation
endproduct, hydroimidazolone MG-H1, linked to protein inactivation and cell dysfunction (4;
5) (Fig. 1B). Degradation of methylglyoxal-modified proteins releases MG-H1 free adduct
from tissues for urinary excretion (4). The steady-state level of protein MG-H1 is maintained
at low tolerable levels by Glo1 (3).
Abnormally high methylglyoxal concentration, dicarbonyl stress, is a common
characteristic of obesity and type 2 diabetes. It is severe in diabetes, driven by increased flux
of methylglyoxal formation and decreased Glo1 activity at sites of vascular complications.
Methylglyoxal is formed mainly by the non-enzymatic degradation of triosephosphate
intermediates of glycolysis – a minor “leak” of ca. 0.05% triosephosphate flux. In obesity,
dicarbonyl stress is mild and triosephosphate flux is increased by glyceroneogenesis in adipose
tissue-liver cycling of triglycerides and free fatty acids. Increased methylglyoxal protein
modification in dicarbonyl stress is implicated as a mediator of impaired metabolic and
vascular health in obesity and diabetes (3).
An effective strategy to counter dicarbonyl stress is to increase expression of Glo1 (6).
We described a functional regulatory antioxidant response element (ARE) in human GLO1
with basal and inducible expression up-regulated by transcriptional factor Nrf2. Recent
advances in Nrf2 regulation suggested potent induction of Glo1 expression could be achieved
by a synergistic combination of Nrf2 activators addressing different regulatory features (7; 8).
In this study we sought to screen dietary bioactive compounds for Glo1 inducer activity in a
functional reporter assay, confirm hits in cell culture and evaluate an optimised Glo1 inducer
formulation in randomised, placebo-controlled crossover clinical trial for improved metabolic
and vascular health in overweight and obese subjects.
RESEARCH DESIGN AND METHODS
Methods
Screening of Glo1 inducers using GLO1-ARE and related stable transfectant reporter
cells lines
Stable transfectant luciferase reporter cell lines with ARE transcriptional regulatory elements
were developed from human HepG2 cells, as described for quinone reductase ARE (7),
incorporating regulatory elements: GLO1-ARE or functionally inactive mutant as negative
control (ARE-1 and ARE1m in previous work) (6). Stable transfectant cell lines were
incubated with and without bioactive compounds (0.625 – 20.0 μM) for 6 h.  Luciferase 
activity was then determined in cell lysates, correcting for blank response and normalised to
the highest effect (100%) achieved with 10 μM trans-resveratrol (tRES) (6). Nrf2-dependent
transcriptional response was verified by siRNA silencing of Nrf2. Cytotoxicity was assessed
after 24 h exposure by the MTT method (9). Screening hit criteria were: increased
transcriptional response at ≤5 μM without significant cytotoxicity to human aortal endothelial 
4cells (HAECs) and BJ fibroblasts in primary culture. Dietary bioactive compound selection
criteria were: ability to activate Nrf2 at concentrations achieved or likely achievable at
tolerable doses clinically and/or decrease glycation and/or toxicity by methylglyoxal or
similar compounds.
ARE-linked gene and other cell metabolism and functional marker gene expression by
digital mRNA profiling and immunoblotting
HAECs, BJ fibroblasts and HepG2 cells (5 x 105 cells/well) were seeded on 6-well plates in
MCDB-131 medium and cultured overnight at 37 oC under 5% CO2/air. Cells were treated
with and without 5 μM tRES, 5 μM hesperetin (HESP) and 5 μM tRES & HESP combined  
or vehicle (0.002% dimethylsulfoxide) and cultured further for up to 48 h. At time points
indicated mRNA was extracted and analysed by the NanoString nCounter method (10).
Immunoblotting was performed as described (6).
Clinical study
A randomized, double-blind, placebo-controlled crossover study of optimised Glo1 inducer
was performed in 32 overweight and obese healthy subjects (Healthy Ageing through
functional food, HATFF). The study was approved by National Research Ethics Service
Committee West Midlands - Coventry & Warwickshire (project number 13/WM/0368) and
registered on the Clinicaltrials.gov (identifier: NCT02095873). The procedures followed
were in accordance with institutional guidelines and the Declaration of Helsinki. Three
participants failed to complete the study.
Main inclusion criteria were: age 18 – 80 years, BMI 25 – 40 kg/m2 and normal, impaired
fasting or impaired postprandial glucose. Main exclusion criteria were: severe
hypertriglyceridemia, uncontrolled hypertension, cardiovascular disease, relevant renal or
hepatic disease, diabetes, and other relevant morbidity; severe excess alcohol consumption
(>14/21 units [8g]/week for women/men), smoking, under pharmacological treatment
affecting glucose and lipid metabolism or blood coagulation, or taking herbal remedies,
known food allergies, women who are pregnant or breast feeding. All subjects were evenly
randomised in tRES-HESP and placebo arms (n = 16) by the Clinical Trials Unit, University
of Warwick. Treatment was one capsule daily for 8 weeks and washout period of 6 weeks:
tRES-HESP - 90 mg tRES-120 mg HESP; and placebo – with starch in place of bioactives in
hard gelatin capsules. Previous studies with dietary fibre supplementation indicated intervention
for at least 8 weeks is required for improved glycemic control (11). Participants were advised to
maintain their usual diet - confirmed by dietary questionnaires at the start and end of dosing
periods, and physical activity - supported by nurse and dietician contact throughout the study.
Primary clinical endpoints were: metabolic health – Oral Glucose Insulin Sensitivity
(OGIS) index in an oGTT (75 g glucose; participants instructed to eat carbohydrate rich diet,
> 150 g/day, for at least three days before the test, followed by an overnight fast) (12); and
vascular health - brachial artery flow mediated dilatation (FMD), including dilatation response
to a subtherapeutic dose (25 µg) glyceryl nitrate (GTND) (13). oGTT and FMD/GTND
assessments were performed at the start and end of each treatment period between 8 am and
10 am in a quiet temperature-controlled room maintained at 23 ± 1 oC. Markers of vascular
inflammation were also assessed by commercial ELISA.
Venous blood samples were also drawn in the fasting state prior to the oGTT. Safety
assessment of tRES-HESP co-formulation was assessed by electrocardiogram and analysis
of blood markers. Plasma methylglyoxal and glycation and oxidation adducts in plasma
protein and urine (second void after overnight fast) were assayed by stable isotopic dilution
analysis liquid chromatography-tandem mass spectrometry (LC-MS/MS) (14; 15).
5Total tRES and HESP urinary metabolites
These were determined by stable isotopic LC-MS/MS after de-conjugation of glucuronides
and sulphates. Urine (20 μl), from which cells had been sedimented and removed prior to 
storage, with 42 mM ammonium acetate buffer, pH 4.9 (60 μl), internal standards (250 µM 
[13C6]tRES and 10 µM d4-HESP; 20 µl) and  β-glucuronidase (5 µl, 85 U) and β-sulphatase (5 
µl, 5 U) was incubated for 2 h at 37 oC in the dark. De-conjugation was validated with
authentic glucuronides and sulphates of tRES and HESP before use. Thereafter ice-cold
methanol (100 µl) was added for de-proteinisation, centrifuged (10,000g, 10 min, 4 oC) and
analysed by LC-MS/MS. Calibration curves were constructed by analysis of 125 – 625 pmol
tRES and HESP.
Cellular GSH and oxidised glutathione GSSG
These were assayed by stable isotopic dilution analysis LC-MS/MS. Cells (ca. 1 x 106 cells)
were deproteinized with 10% trichloroacetic acid (40 µl) containing 0.15% NaCl and 0.25%
sodium azide in water and centrifuged (20,000g, 30 min, 4 °C). An aliquot of supernatant
(10 µl) was mixed with 10 µl isotopic standard cocktail (100 pmol [13C2,15N]GSH and
[13C4,15N2]GSSG) and analysed by LC-MS/MS. Calibration standards contained 100 - 2000
pmol GSH and 5-100 pmol GSSG (Fig. 3).
Statistical analysis
Data are mean ± SD or SEM for parametric data and median (upper – lower quartile) for non-
parametric data. Significance testing in paired data was assessed by paired Student’s t-test
and Wilcoxon signed-ranks test (for 2 two groups), by ANOVA repeated measures and
Friedman test (for 4 or more groups), and correlation analysis by Pearson and Spearman
methods for parametric and non-parametric data, respectively. For HATFF study power
calculation, we judged decrease in AUCg of the oGTT would be 10%; cf. 30% decrease with
high cereal fibre intake (16). With a 30% dropout, 32 subjects were required for α = 0.05 and 
power (1 – β) = 0.80. Post-hoc analysis of variables for highly overweight and obese sub-
groups was performed to explore BMI as a factor influencing responsiveness to Glo1
inducers.
RESULTS
Screening of small molecule Glo1 inducers
After screening of ca. 100 dietary bioactive compounds with Nrf2 activator activity, the
highest Emax was produced by tRES. The lowest EC50 for GLO1-ARE transcriptional activity
was found with HESP. For tRES, EC50 = 2.52 ± 0.19 µM and Emax 100 ± 2 %; and for HESP,
EC50 = 0.59 ± 0.01 µM and Emax 24.4 ± 0.1 % (Fig. 2 A, B). In previous clinical studies, dietary
supplementation of 150 mg HESP achieved a peak plasma concentration of 6.7 µM (17),
suggesting that HESP may be a competent Glo1 inducer for clinical use but with low maximal
effect; and dietary supplementation of 500 mg tRES achieved a peak plasma concentration of
ca. 0.3 µM (18), 8-fold lower than the EC50 for GLO1-ARE response. To enhance efficacy we
studied the pharmacological synergism of tRES and HESP together. Study of the GLO1-ARE
transcriptional response of 5 µM HESP with 0.625 – 10 µM tRES showed that HESP combined
synergistically with tRES, decreasing the EC50 of tRES ca. 2-fold to 1.46 ± 0.10 µM whilst
maintaining the Emax (Fig. 2C). The predicted increase of GLO1-ARE transcriptional response
from concentration response curves of 0.1 – 1.0 tRES in the presence of 5 µM HESP was 3 – 79
fold, including up to 80% increase over additive effects (Fig. 2D). This suggests marked benefits
may accrue from use of tRES-HESP co-formulation.
6Safety assessments of tRES and HESP indicate that they are highly tolerated (19; 20).
Studies of human BJ fibroblasts in primary culture showed no toxicity of tRES and HESP
individually or with 5 μM combination with primary bioactive compound at concentrations ≤ 20 
μM. tRES (40 μM) with 5 μM HESP and 40 μM HESP with and without 5 μM tRES showed 
minor decrease in viability of BJ cells in vitro (Fig. 2E-2F).  tRES (5 μM) with 0.625 μM HESP 
gave a minor increase in cell number – possibly an effect of insulin sensitising activity (see
below). There was no toxicity of tRES, HESP and both combined in human aortal endothelial
cells (HAECs) in primary culture under similar conditions (Fig. 2G-2H).
Validation of Glo1 inducer screening results and functional effects
To validate the Glo1 inducer studies we measured the change in Glo1 mRNA and protein and
functional responses in human hepatocyte-like HepG2 cell line in vitro and HAECs and BJ
fibroblasts in primary culture. There was a 10 – 30% increase in Glo1 mRNA in cells incubated
with tRES and HESP and combined, and similar increases in Glo1 protein (Fig. 2I-2K). We then
studied the effect on functional markers: inflammatory response proteins and matrix
metalloproteinase. In HAECs, treatments decreased intercellular adhesion molecule-1 (ICAM-
1), receptor for advanced glycation endproducts (RAGE) and E-selectin protein, with
synergistic effects on ICAM-1 and RAGE (Fig. 3A-3C). In BJ fibroblasts, treatments
decreased cellular vascular adhesion molecule-1 (VCAM-1), RAGE and matrix
metalloproteinase-3 (MMP-3), with synergism for tRES and HESP in decrease of VCAM-1
and MMP-3 (Fig. 3D - 3F). This suggests that the tRES and HESP treatment lowers basal cell
inflammation and extracellular matrix turnover.
Activation of Nrf2 is associated with increased cellular GSH and GSH/oxidised
glutathione (GSSG) ratio through increased expression of genes of GSH synthesis and
metabolism – particularly γ-glutamylcysteine ligase [modulatory and catalytic subunits] 
(GCLM and GCLC) and glutathione reductase (GSR). Treatment of HAECs, BJ fibroblasts
and HepG2 cells in vitro with 5 μM tRES and 5 μM HESP individually, however, did not 
change cellular levels of GSH and GSSG whereas treatment with 5 μM tRES and HESP 
combined increased cellular GSH content by 43% in BJ fibroblasts and 32% in HepG2 cells
(Fig. 3G-3L). Increased cellular GSH concentration enhances in situ activity of Glo1 (3).
We also studied time-dependent changes in expression of ARE-linked genes and other
genes linked to metabolism and function in HAECs, BJ fibroblast and HepG2 cells by focussed
quantitative mRNA array (selected time course responses are given in Supplementary Fig. 1A–
1C). Overall, there were additive and synergistic changes on gene expression of tRES and HESP
combined treatment. For example, in HAECs, mRNA of ARE-linked genes glutathione
transferase A4 (GTSA4), heme oxygenase-1 (HMOX-1), GCLM, GCLC and GSR, were
increased. tRES and HESP together decreased ICAM-1 mRNA. In BJ fibroblasts, tRES and
HESP synergised to increase mRNA of GSTP1, HMOX1, NQO1 and aldoketo reductase 1C1
(AKR1C1) and to decrease expression of inflammation markers CCL2 and ICAM-1. In HepG2
cells, tRES and HESP combined synergistically to increase mRNA of NQO1, GCLM and
GCLC, low density lipoprotein receptor (LDLR), hexokinase-2 (HK2) and 6-
phosphofructokinase/bisphosphatase-3 (PFKBP3).
Improved clinical metabolic and vascular health with tRES-HESP co-formulation –
HATFF study
Co-formulation of tRES-HESP was evaluated in healthy overweight and obese subjects.
Twenty-nine subjects completed the study. Characteristics of subjects at study entry are given
(Table 1). Subjects had mildly impaired glycemic control with only 9 subjects meeting criteria
of prediabetes; all participants were overweight or obese, 20 were highly overweight (BMI >
27.5 kg/m2), and 11 were obese (BMI > 30 kg/m2). tRES-HESP treatment increased urinary
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to placebo (Supplementary Fig. 2A-2B). Dietary questionnaires, urinary excretion of pyrraline
- an advanced glycation endproduct sourced only from food (21), and fasting plasma ketone
body concentrations in the normal range in all subjects (22) suggested food consumption was
similar throughout the study (Table 2). Clinical safety indicators were normal at study entry
and remained unchanged throughout the placebo and tRES-HESP treatment periods
(Supplementary Table 1).
tRES-HESP produced a 22% increase in Glo1 activity of peripheral blood mononuclear
cells (PBMCs) post-treatment, compared to placebo in all subjects. PBMC Glo1 activity was
increased 27% in highly overweight/obese and 30% in obese sub-groups. Concomitant with this
there was a 37% decrease in plasma methylglyoxal post-supplementation with tRES-HESP but
not with placebo in highly overweight/obese subjects. There was no change in plasma D-lactate
concentration with tRES-HESP treatment - a surrogate indicator of flux of methylglyoxal
formation (3) (Table 2). Therefore, increase of Glo1 activity by tRES-HESP in PBMCs, also
expected in tissues, likely decreased plasma methylglyoxal concentration without change in flux
of methylglyoxal formation.
With tRES-HESP treatment, there was a positive correlation of change in OGIS from
baseline (ΔOGIS) with BMI; r = 0.45, P<0.05 (Fig. 4A). No similar correlation occurred with 
placebo. In the subset of highly overweight subjects, there was an increase in OGIS from
baseline with tRES-HESP (ΔOGIS = +42 mlmin-1m-2; Table 2; Fig. 4B) but not with placebo.
This effect was further enhanced in obese subjects only (ΔOGIS = + 58 mlmin-1m-2) (Table
2). The main contributory factors to this effect were: (i) decreased fasting plasma glucose
(FPG) [P<0.01]; and (ii) decreased area under the curve plasma glucose (AUCg) [P<0.03,
ANOVA] (Table 2).
There was a negative correlation of change in FPG from baseline (ΔFPG) to BMI with 
tRES-HESP treatment; r = - 0.41, P<0.05 (Fig. 4C). No similar correlation occurred with
placebo. In highly overweight subjects, there was a 5% decrease in FPG post
supplementation with tRES-HESP (Fig. 4D). This effect was further enhanced in obese
subjects only; - 9% (Table 2). There was also decreased AUCg in the oGTT with tRES-HESP
treatment in the highly-overweight study group by a similar extent; - 6%, P<0.03, ANOVA
(Table 2). Therefore, tRES-HESP treatment would likely decrease exposure to increase
glucose concentration in the fasting and postprandial states in the highly overweight and
obese populations.
Concomitant with increased metabolic health there were small decreases in BMI and
body weight in the obese subjects with tRES-HESP: - 0.5 kg/m2 and - 0.3 kg, respectively.
Measurement at morning study visits excluded effect of diurnal variation. Other small
changes were: 3% increase in eGFR and 9% decrease in plasma urea with tRES-HESP.
Further clinical variables unchanged by tRES-HESP treatment are given (Table 2).
In assessment of vascular function, we found no change in FMD and GTND. For
FMD/GTND ratio, normalising from baseline, in the highly overweight/obese subject group,
the 95% confidence interval for ΔFMD/ΔGTND with tRES-HESP was 0.13 – 2.11. 
Assessment of markers of vascular inflammation revealed a decrease in change of sICAM1
from baseline with tRES-HESP in all subjects, compared to increase with placebo: - 3.6 ± 6.9
versus + 25.8 ± 6.9 ng/ml (P<0.01); a reversal of ca. 10% of post-supplementation placebo
level.
To assess the effect on protein glycation in the HATFF study we analysed glycation
and oxidative damage of plasma protein. Plasma protein MG-H1 was unchanged with tRES-
HESP treatment (Table 1). We propose this unexpected finding may be due to improved
vascular function with tRES-HESP treatment, decreasing transcapillary escape rate of
albumin (23), increasing vascular half-life of albumin and thereby maintaining MG plasma
8protein glycation. The increase of transcapillary escape rate of albumin in obesity was 36%
(24) - similar magnitude to the decrease of plasma methylglyoxal herein with tRES-HESP.
The oxidative crosslink dityrosine was decreased 21% with tRES-HESP treatment but not
with placebo (Table 2, Fig. 4E). To assess the whole body formation of MG-H1 we measured
the urinary excretion of MG-H1 free adduct, corrected for MG-H1 absorbed from food by
extrapolating regression of urinary MG-H1 on urinary pyrraline in all subjects to zero
pyrraline (and hence no contribution from food) (25; 26) (Fig. 4F). The flux of endogenously-
generated MG-H1 adducts was ca. 13 nmol/mg creatinine at baseline and decreased by 14%
with tRES-HESP treatment but not with placebo (Table 2, Fig. 4G). The pentose-derived
crosslink, pentosidine, is a quantitatively minor and fluorescent glycation adduct. Urinary
excretion of pentosidine free adduct was decreased 32% by treatment with tRES-HESP but
not by placebo (Fig. 4H).
We analysed changes in gene expression of PBMCs in a focused quantitative mRNA
array study. In all subjects there was increased expression of GLO1 and decreased
inflammation-linked genes, IL8 and PTGS2. In obese subjects there was also decreased
expression of CCL2 and TNFA (Table 3)
DISCUSSION
Pharmaceutical doses of two dietary compounds, tRES found in red grapes and HESP closely-
related to hesperidin found in oranges, administered together acted synergistically to improve
FPG, AUCg, OGIS, sICAM-1, arterial function and renal function in highly-overweight
subjects. Most clinical effects were found in the highly overweight subgroup (BMI >27.5
kg/m2), indicating that the tRES-HESP co-formulation has decreasing potency as the lean range
of BMI is approached. This suggests a re-setting to good metabolic and vascular health.
tRES and HESP administered individually in previous studies was ineffective. From
meta-analysis it was concluded that tRES does not affect glycemic status in overweight and
obese human subjects (27). This is at odds with evidence from rodent models (28) and is
likely due to interspecies differences in pharmacology, host interactions and maximum
tolerable dose. HESP absorbed from clinical dosing with hesperidin did not improve plasma
glucose nor insulin resistance (29).
We arrived at the tRES-HESP formulation through maximising induction of Glo1
expression. Whilst increased Glo1 expression likely contributes to the observed health beneficial
effects (3), changes in other gene expression occurred – such as induction of antioxidant
enzymes and GSH synthesis (Fig. 3H,3I and Supplementary Fig. 1), and their interplay may also
mediate the overall health benefit achieved. We exploited the regulatory ARE of GLO1 to
increase expression (6). We limited the small molecule inducer screen to non-toxic dietary
bioactive compounds of known or suspected Nrf2 activation activity to provide an option for use
of Glo1 inducers as functional food supplements as well as pharmaceuticals. tRES and HESP
also have > 50-fold safety margin at doses used in the HATFF study (19; 20). Activation of
Nrf2 by dietary bioactive compounds is mostly studied through ARE-linked induction of NQO1
or HMOX1 expression. Small molecule activators of Nrf2 increase expression of different ARE-
linked gene subsets (6; 7) - likely due to the ability of Nrf2 activators to recruit the requisite
accessory proteins and increase nuclear concentration of functionally active Nrf2 to the level
required for increased expression of the ARE-linked gene of interest (7; 8). A specific functional
screen for GLO1-ARE transcriptional activation was therefore required.
Activation of Nrf2 by tRES has been studied previously by induction of HMOX1
expression (30). Herein we found tRES also induces expression of Glo1 with high Emax. Our
recent studies (7; 8) and of others (31) suggest this is achieved by preventing nuclear acetylation
and inactivation of Nrf2 via increasing in situ activity of sirtuin-1. At low tRES concentrations,
this occurs through inhibition of cAMP phosphodiesterases, activation of AMPK and increased
9NAD+. HESP may also synergise for increased activity of sirtuin-1 through activation of AMPK
by the protein kinase A pathway (32; 33).
Clinically achievable concentrations of tRES at highly tolerable doses are lower than the
EC50 for induction of Glo1 expression, however, so synergism with HESP is required to achieve
increase Glo1 expression in clinical translation. HESP may activate Nrf2 through induction and
activation of protein kinase A, upstream of fyn kinase which drives Nrf2 translocational
oscillations and ARE-linked gene expression (8; 33). HESP is a partial agonist (Fig. 2B) which
is likely due to inhibitory nuclear acetylation of Nrf2 blocking a high Emax. Combination with
tRES and HESP provides for faster nuclear translocation and decreased inactivation of Nrf2 (7;
8; 31). Use of HESP rather than related dietary glycoside hesperidin found in citrus fruits (34) is
likely crucial: HESP has ca. 70-fold greater potency in Nrf2 activation and higher bioavailability
than hesperidin (35).
tRES-HESP increased OGIS to levels typical of healthy, lean subjects. The magnitude
of ΔOGIS, 42 – 58 mlmin-1m-2, is comparable to that achieved with pharmaceutical treatment
of patients with type 2 diabetes (for example, 1.7 g metformin per day, ΔOGIS = +54 mlmin-
1m-2) (36) and extreme weight loss with gastric band surgery in morbid obesity (ΔOGIS = 
+62 mlmin-1m-2) (37). These effects suggest the tRES-HESP can support therapeutic
improvement of insulin sensitivity in highly-overweight populations. OGIS was initially
proposed as a marker of insulin resistance but is also improved with increased β-cell sensitivity
to glucose and decreased glucose absorption (38). Regarding insulin resistance, decreased
activity of FGF21 due to down regulation of the FGF21 receptor cofactor β-Klotho may be 
involved (39). MG-driven protein glycation decreased expression of β-Klotho (40). By inducing 
Glo1 expression and decreasing MG protein glycation, therefore, we likely corrected the
functional deficit of β-Klotho and re-engaged FGF21. This explains the resetting of insulin 
sensitivity to normal levels with the response greater for higher BMI subject groups.
Characteristics of increased β-Klotho was its blocking of inflammatory signalling to down 
regulate pro-inflammatory mediators IL8, MCP1, ICAM1 and RAGE (40), and via decreasing
MCP-1 also suppresses PTGS2 (41) – Fig. 5. All features of this transcriptional signature were
found in PBMCs of the HATFF study. Other effects increasing OGIS may be: increased
pancreatic beta-cell sensitivity to glucose (42), decreased intestinal absorption of glucose (43),
changes of gut microbiota and decreased breakdown and absorption of starch (44) (Fig. 5).
The 5% decrease in FPG herein exceeds and matches effects of metformin and
Olristat, respectively, in similar intervention trials in overweight/obese subjects (45; 46),
Decrease in FPG in the normal range is associated with reduced risk of developing type 2
diabetes (47).
Decreased urinary excretion of pentosidine by tRES-HESP may be linked to
decreased oxidative stress and decreased pentose precursors expected from improved insulin
resistance (48).
tRES-HESP treatment produced an increase in ΔFMD/ΔGTND. The effect is likely 
produced by improved NO responsiveness in both endothelium and smooth muscle cells (13)
related to induction of Glo1 and prevention of MG-glycation driven impairment of
endothelial NO synthase (49). tRES-HESP also decreased dityrosine content of plasma
protein. Dityrosine is an oxidative crosslink of tyrosine residues and is a dominant crosslink
of the extracellular matrix (50). Plasma protein dityrosine may be a surrogate marker of this
and hence be reporting decreased dityrosine crosslinking which may contribute to improved
arterial function.
tRES-HESP decreased sICAM1 in the HATFF study. The cell studies herein suggest
this is likely linked to decreased ICAM1 expression. ICAM1 expression was decreased in
Glo1 transgenic rats (51). In clinical studies, tRES and HESP individually did not decrease
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ICAM-1 (52; 53). sICAM1 correlates with atherosclerosis burden assessed by coronary artery
calcification and is a risk predictor of cardiovascular disease (54).
In summary, we present evidence that pharmaceutical doses of tRES and HESP co-
formulation produce improved metabolic and vascular health in overweight and obese subjects.
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Table 1. Characteristics of subjects in the HATFF study at entry.
Variable Value
Age (years) 45 ± 13
Gender (M/F) 8/21
BMI (kg/m2) 30.0 ± 3.8
Overweight/Obese 18/11
Fasting plasma glucose (mM) 3.93 ± 0.57
A1C (mmol/mol Hb)
(%)
36.2 ± 4.3
5.5 ± 0.7
Prediabetes (N/Y) 20/9
GFR (ml/min) 97 ± 17
Systolic BP (mmHg) 133 ± 12
Diastolic BP (mmHg) 83 ± 10
Hypertension (N/Y) (18/11)
Data are mean ± SD, median (lower – upper quartile) or number of each classification (class
1/class 2); n = 29. Hypertension was defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 
mm Hg on 4 occasions. Thirty-two subjects were recruited at the University Hospitals
Coventry & Warwickshire NHS Trust, Coventry, U.K. in the period May – July 2014; the last
participant left the study December 2014. At pre-screening, assessments made were: 2 h
plasma glucose in an oral glucose tolerance test (oGTT) and A1C, aspartate transaminase,
alanine transaminase, plasma triglycerides, plasma creatinine (for estimated glomerular
Table 1. Characteristics of subjects in the HATFF study at entry (cont’d).
filtration rate eGFR). One participant was withdrawn from the study for diverging from the
protocol and 2 dropped out – one whilst on placebo and one on treatment. The 2 participants
that dropped out stated personal reasons, related to interfering duties and therefore difficulties
to attend the scheduled follow up appointments. None of the participants reported any
relevant side effects (nausea, loss of appetite, gastrointestinal side effects and other
symptoms). Study data are analysed per protocol (n = 29).
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Table 2. Improvement of metabolic health with trans-resveratrol-hesperetin co-formulation in the HATFF study.
Variable Study group Placebo tRES-HESP Δ + tRES-HESP from: baseline [post-supplement]
Significance P from:
baseline [post-supplement]
ANOVA/
FriedmanBaseline Post-supplement Baseline Post-supplement
Urinary pyrraline
(nmol/mg creatinine)
All 12.1 (6.4 – 15.8) 10.6 (7.8–15.0) 8.8 (5.1–13.4) 8.2 (5.1– 21.3) ---- [ ---- ] ---- [ ---- ] ----
PBMC Glo1 activity
(mU/mg protein)
All 1300 ± 136 1155 ± 151 1343 ± 156 1414 ± 150 ---- [+259 (+22%)] ---- [<0.05] <0.02
Highly-
overweight
1346 ± 154 1156 ± 185 1345 ± 189 1463 ± 177 ---- [+ 307 (+27%)] ---- [<0.05] <0.02
Obese 1451 ± 242 1085 ± 253 1140 ± 246 1413 ± 264 ---- [+ 328 (+30%)] ---- [<0.05] ----
Plasma methylglyoxal
(nM)
Highly
overweight
166 ± 28 228 ± 30 160 ± 29 133 ± 18 ---- [- 84 (- 37%)] ---- [<0.05] ----
Plasma D-lactate (μM) All 8.28 ± 0.81 8.56 ± 0.73 7.46 ± 0.77 8.31 ± 0.73 ---- [ ---- ] ---- [ ---- ] ----
OGIS
(mlmin-1m-2)
Highly-
overweight
513 ± 23 541 ± 21 506 ± 22 548 ± 23 42 (+8%) [ ---- ] <0.02 [ ---- ] <0.05
Obese 488 ± 32 522 ± 32 489 ± 29 547 ± 30 58 (+12%) [ ---- ] <0.02 [ ---- ] ----
Fasting plasma insulin
(pM)
All 39.6 ± 6.3 38.2 ± 5.2 43.1 ± 6.9 36.0 ± 3.2 ---- [ ---- ] ---- [ ---- ] ----
Plasma insulin (pM;
oGTT, 90 min)
Highly
overweight
291 (142 – 487) 326 (223 – 422) 303 (177 – 508) 240 (110 – 452) ---- [ ---- ] ---- [ ---- ] ----
FPG (mM) Highly
overweight
3.92 ± 0.12 3.80 ± 0.13 4.02 ± 0.15 3.82 ± 0.16 - 0.20 (- 5%) [ ---- ] <0.04 [ ---- ] <0.01
Obese 3.76 ± 0.11 3.80 ± 0.16 3.92 ± 0.16 3.58 ± 0.16 - 0.34 (- 9%) [ ---- ] <0.02 [ ---- ] <0.05
AUCg (mM h) Highly
overweight
11.0 ± 0.7 10.5 ± 0.6 10.8 ± 0.7 9.9 ± 0.6 - 0.6 (- 6%) [ ---- ] 0.052 [ ---- ] <0.03
BMI (kg/m2) Obese 34.2 ± 0.7 34.3 ± 0.6 34.0 ± 0.7 33.8 ± 0.6 ---- [- 0.5 (- 1%)] ---- [<0.05] <0.02
Body weight (kg) Obese 93.2 (84.0-109.4) 93.6 (84.1–108.8) 93.8(83.7-106.6) 93.3(83.2–107.7) ---- [- 0.3 (- 0.3%)] ---- [<0.05] ----
eGFR (ml/min) All 99 ± 2 101 ± 2 97 ± 2 100 ± 2 + 3 (+3%) [ ---- ] <0.03 [ ---- ] <0.02
Plasma urea (mM) All 4.60 ± 0.19 4.35 ± 0.18 4.67 ± 0.17 4.23 ± 0.15 - 0.44 (- 9%) [ ---- ] <0.01 [ ---- ] <0.01
Plasma acetoacetate
(μM) 
All 61 (42-135) 74 (49-113) 62 (48-127) 77 (65-125) ---- [ ---- ] ---- [ ---- ] ----
Plasma β-hydroxy-
butyrate (μM) 
All 27 (16 – 47) 24 (13 – 46) 26(18 – 49) 22 (11 – 46) ---- [ ---- ] ---- [ ---- ] ----
A1C (mmol/mol)
(%)
All 36.7 ± 0.8
5.5 ± 0.1
36.5 ± 0.8
5.5 ± 0.1
36.8 ± 0.8
5.5 ± 0.1
36.5 ± 0.9
5.5 ± 0.1
---- [ ---- ] ---- [ ---- ] ----
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Table 2. Improvement of metabolic health with trans-resveratrol-hesperetin co-formulation in the HATFF study (cont’d).
Variable Studygroup
Placebo tRES-HESP Δ + tRES-HESP from: 
baseline [post-supplement]
Significance P from:
baseline [post-supplement]
ANOVA/
FriedmanBaseline Post-supplement Baseline Post-supplement
2h Glucose, oGTT
(mM)
All 4.28 ± 0.32 4.20 ± 0.26 4.40 ± 0.29 4.40 ± 0.26 ---- [ ---- ] ---- [ ---- ] ----
HOMA-IR (mM x
mU/L)
All 0.75 (0.46–1.22) 0.68 (0.42 – 1.25) 0.85 (0.38–1.56) 0.69 (0.49–1.34) ---- [ ---- ] ---- [ ---- ] ----
Systolic BP (mmHg) All 131 ± 2 132 ± 3 131 ± 3 133 ± 3 ---- [ ---- ] ---- [ ---- ] ----
Diastolic BP (mmHg) All 81.7 ± 1.9 82.9 ± 2.3 83.4 ± 2.1 83.3 ± 2.3 ---- [ ---- ] ---- [ ---- ] ----
Total cholesterol (mM) All 5.48 ± 0.39 5.72 ± 0.28 5.35 ± 0.31 5.53 ± 0.28 ---- [ ---- ] ---- [ ---- ] ----
LDL/VLDL cholesterol
(mM)
All 3.93 ± 0.26 4.16 ± 0.23 4.01 ± 0.23 4.06 ± 0.23 ---- [ ---- ] ---- [ ---- ] ----
HDL cholesterol (mM) All 1.36 ± 0.10 1.39 ± 0.11 1.36 ± 0.10 1.37 ± 0.11 ---- [ ---- ] ---- [ ---- ] ----
Triglycerides (mM) All 0.810 ± 0.132 0.719 ± 0.122 0.650 ± 0.110 0.655 ± 0.092 ---- [ ---- ] ---- [ ---- ] ----
Endothelin-1 (pg/ml) All 1.66 ± 0.17 1.61 ± 0.14 1.66 ± 0.12 1.64 ± 0.15 ---- [ ---- ] ---- [ ---- ] ----
CRP (μg/ml) All 2.32 (0.99–5.46) 2.37 (0.63–3.75) 2.23 (0.82–3.97) 1.74 (0.76–3.91) ---- [ ---- ] ---- [ ---- ] ----
sE-selectin (mg/ml) All 39.0 ± 2.9 38.8 ± 3.2 39.2 ± 3.0 38.3 ± 3.0 ---- [ ---- ] ---- [ ---- ] ----
sVCAM1 (ng/ml) All 453 ± 16 449 ± 13 437 ± 12 445 ± 14 ---- [ ---- ] ---- [ ---- ] ----
Cystatin-c (ng/ml) All 676 ± 28 678 ± 29 692 ± 32 691 ± 31 ---- [ ---- ] ---- [ ---- ] ----
Albumin/creatinine
ratio (mg albumin/
mmol creatinine)
All 0.257 (0.171–0.483) 0.261 (0.147–0.790) 0.231 (0.150–0.465) 0.264 (0.159–0.581) ---- [ ---- ] ---- [ ---- ] ----
FMD (mm) All 0.18 (0.07 – 0.49) 0.26 (0.07 – 0.47) 0.17 (0.10 – 0.35) 0.12 (0.06 – 0.31) ---- [ ---- ] ---- [ ---- ] ----
GTND (mm) All 0.41 (0.36 – 0.77) 0.44 (0.28 – 0.76) 0.45 (0.37– 0.75) 0.38 (0.29– 0.53) ---- [ ---- ] ---- [ ---- ] ----
Plasma sICAM1 All 257 ± 13 284 ± 15 280 ± 13 276 ± 13 ---- [ ---- ] ---- [ ---- ] <0.01
Plasma protein MG-H1
(mmol/mol arg)
All 0.370 (0.348–0.447) 0.380 (0.340–0.420) 0.357 (0.330–0.408) 0.381 (0.353–0.416) ---- [ ---- ] ---- [ ---- ] ----
Plasma protein
dityrosine (μmol/mol 
tyr)
All 28.6 ± 2.7 26.6 ± 2.6 29.6 ± 2.9 23.5± 1.7 - 6.1 (- 21%) [ ---- ] < 0.01 [ ---- ] <0.02
Total urinary MG-H1
free adduct (nmol/mg
creatinine)
All 20.1 (16.3 – 30.6) 22.7 (16.6 – 29.3) 19.7 (12.5 – 30.4) 19.8 (14.9 – 27.4) ---- [ ---- ] ---- [ ---- ] ----
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Table 2. Improvement of metabolic health with trans-resveratrol-hesperetin co-formulation in the HATFF study (cont’d).
Variable Studygroup
Placebo tRES-HESP Δ + tRES-HESP from: 
baseline [post-supplement]
Significance P from:
baseline [post-supplement]
ANOVA/
FriedmanBaseline Post-supplement Baseline Post-supplement
Endogenous urinary
MG-H1 free adduct
(nmol/mg creatinine)
All 13.4 ± 2.1 13.5 ± 3.7 13.1 ± 2.8 11.3 ± 3.1 - 1.8 (-14%) [ ---- ] <0.01 [<0.01] <0.01
Urinary pentosidine
free adduct (pmol/mg
creatinine)
All 10.8 (6.8 – 20.2) 12.7 (5.7 – 23.6) 10.8 (7.4 – 21.8) 7.4 (4.3 – 16.5) - 3.4 (- 32%) [ ---- ] <0.05 [ ---- ] -----
Data are mean ± SEM or median (lower – upper quartile). For obese, highly overweight/obese and all study groups, n = 11, 20 and 29,
respectively. Variables failing to achieve or approach significance are given in Table S1. tRES-HESP treatment changes, Δ + tRES-HESP, are 
absolute (percentage) changes from baseline and similarly changes with respect to post-supplement placebo control in square brackets [ ].
Related significance levels are also given where P<0.05 and, in one case, borderline failure of significance, P = 0.052. There were not statistical
significance differences induced by placebo.
Table 3. Summary of change in gene expression of PBMC with trans-resveratrol-hesperetin co-formulation in the HATFF study.
Study group GenesIncreased Decreased
All (n = 29) GLO1 (+6%) HIF1A (- 6%), IL8 (- 39%) and PTGS2 (- 30%)
Highly overweight/obese (n = 20) ---- FTH1 (- 19%), HIF1A (- 8%), IL8 (- 49%), PTGS2 (- 31%), RAGE (- 37%) and CCL2 (- 49%)
Obese (n = 11) ---- CCL2 (- 22%), HIF1A (- 7%), IL8 (- 62%), KEAP1 (- 18%), PTGS2 (- 37%) and TNFA (- 12%)
Data and statistical analysis are given in Supplementary Table 2.
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Figure legends.
Figure 1. Glyoxalase pathway and protein glycation by methylglyoxal. A: Metabolism of
methylglyoxal by the glyoxalase system. B: Formation of hydroimidazolone MG-H1 from
arginine residues in protein.
Figure 2. Induction of glyoxalase 1 expression by trans-resveratrol and hesperetin.
GLO1-ARE transcriptional response reporter assay. Data of normalised responses for varied
bioactive concentrations were fitted by non-linear regression to the equation E = Emax x
[Bioactive]n/(EC50n + [Bioactive]n), solving for Emax, EC50 and n (Hill coefficient). A:
Concentration-response curve for tRES. Data are mean ± SD (n = 3) for 5 concentrations.
Non-linear regression (red curve): E (%) = 100 x [tRES]3.92/( 2.523.92 + [tRES]3.92). B:
Concentration-response curve for HESP. Data are mean ± SD (n = 3 - 8) for 6 concentrations.
Non-linear regression (blue curve): E (%) = 24.4 x [HESP]2.01/(0.59.2.01 + [HESP]2.01). C:
Concentration-response curve for tRES in the presence of 5.0 μM HESP. Data are mean ± SD 
(n = 3 - 6) for 5 concentrations. Non-linear regression (black curve): E (%) = (83.4 x
[tRES]1.36/(1.46.1.36 + [tRES]1.36)) + 11.6;  green curve – tRES+ 5.0  μM HESP,  red dotted 
curve – tRES only (as for A:). D: Expansion of C: also showing the response for 5.0 μM HESP 
(blue dashed line). E - H: Evaluation of the effect of tRES and HESP individually and in
combination on the growth and viability of BJ fibroblasts [E and F] and HAECs [G and H] in
vitro. For E and G cells were incubated with 0.625 – 40 μM tRES and with (green bars) or 
without (red bars) 5.0 μM HESP. For F and H cells were incubated with 0.625 – 40 μM HESP 
and with (green bars) or without (blue bars) 5.0 μM tRES. I - K Validation of induction of Glo1
expression by 5.0 μM tRES and HESP, individually and combined. Cell type:  I , HAECs; J, BJ
fibroblasts; K, HepG2 cells . Panels (from left to right): GLO1 mRNA change with 5.0 μM tRES 
(red line), 5.0 μM HESP (blue line) and 5.0 μM tRES & HESP (green line). Bar chart: Glo1 
protein (16 h post-treatment): + 5.0 μM tRES (red bar) and 5.0 μM HESP (blue bar). Data are 
mean ± SD (n = 3) for E – K. Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001. HAEC
cells were grown in proprietary large vessel endothelial cell basal media supplemented with
large vessel endothelial cell growth supplement (containing hydrocortisone, human epidermal
growth factor, human fibroblast growth factor with heparin and in 2% (/v/) FBS), 25 µg/ml
gentamicin and 50 ng/ml amphotericin B. They were cultured in MEM medium with 10%
fetal calf serum and 2 mM glutamine under an atmosphere of 5% CO2 in air, 100% humidity
and 37oC.
Figure 3. Effect of trans-resveratrol, hesperetin and trans-resveratrol-hesperetin co-
addition on cell vitality markers and glutathione metabolism in human endothelial cells,
fibroblasts and HepG2 cells in vitro. A – F: cell vitality markers. Key: control (black bar), +
5.0 μM tRES (red bar), + 5.0 μM HESP (blue bar) and 5.0 μM tRES & HESP (green bar). 
HAECs: A ICAM1 protein and B RAGE protein at 18 h post-treatment, C E-selectin protein and
D VCAM-1 protein at 24 h post-treatment. BJ fibroblasts: E RAGE protein and F MMP3
protein at 72 h post-treatment. G – L: Cellular GSH and GSSG at 24 h post-treatment: G – I and
J – L, GSH and GSSG in HAECs, BJ fibroblasts and HepG2 cells, respectively. Percentage
change with respect to GSH of control cultures is indicated. Data are mean ± SD [n = 3].
Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001 with respect to control; and o, P<0.05
with respect to tRES control, and “+”, P<0.05 with respect to HESP control. LC-MS/MS was
performed using two Hypercarb HPLC columns in series (50 x 2.1 mm and 250 x 2.1 mm,
particle size 5 µm) at temperature of 30 °C. Initial mobile phase was 0.1% TFA in water and
the elution profile was: 1 – 15 min, a linear gradient of 0 – 30% acetonitrile and 15 – 16 min,
isocratic 30% acetonitrile; the flow rate was 0.2 ml/min and diverted into the mass
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spectrometer from 4 – 16 min. Mass spectrometric analysis was performed using electrospray
positive ionisation mode with detection settings: capillary voltage was 3.4 kV, source and
desolvation gas temperatures 120 °C and 350 °C, cone and desolvation gas flows 146 and
550 l/h, respectively. Analytes detection (retention time, mass transition molecular
ion>fragment ion, cone voltage and collision energy were: GSH – 11.7 min, 308.2>179.1 Da,
30 V and 13 eV; [13C2,15N]GSH – 11.7 min, 311.2>182.1 Da, 30 V and 13 eV; GSSG – 14.4
min, 613.2>483.7 Da, 52 V and 18 eV; [13C4,15N2]GSSG – 14.4 min, 619.2>489.7 Da, 52 V
and 18 eV. For GSH and GSSG, limits of detection were 0.92 pmol and 1.46 pmol,
analytical recoveries 97 ± 2% and GSSG, 93 ± 6%, and intra-batch coefficient of variation
8.8% and 10.9% (n = 6), respectively.
Figure 4. Outcomes from the HATFF clinical study. A: Correlation of change in OGIS
from baseline (ΔOGIS) with BMI in the tRES-HESP treatment arm. r = 0.45, P<0.05 
(Pearson); n = 29. B: OGIS in tRES-HESP treatment arm at baseline [BS] and post-
supplementation [PS] study visits in highly overweight subjects; n = 20. OGIS was calculated
from plasma glucose concentrations at 0, 90 and 120 min and plasma insulin concentrations
at 0 and 90 min (12). C: Correlation of change in FPG from baseline with BMI in the tRES-
HESP treatment arm. r = - 0.41, P<0.05 Pearson; n = 29. D: FPG in tRES-HESP treatment
arm at BS and PS study visits in highly overweight; n = 20. E: Dityrosine residues in plasma
protein at BS and PS study visits; n = 29. F: Regression of urinary excretion of MG-H1 free
adduct on urinary excretion of pyrraline free adduct at baseline of the placebo arm.
Regression line: Urinary MG-H1 (nmol/mg creatinine) = (0.592 ± 0.180) x urinary pyrraline
(nmol/mg creatinine) + (13.4 ± 2.1); P = 0.003. Total urinary excretion of MG-H1 free adduct
correlated positively with urinary pyrraline for all 4 study visits, r = 0.43 – 0.63, P = 0.019 -
<0.001). G: Endogenous flux of MG-H1 formation at study visits. H: Urinary excretion of
pentosidine free adduct at study visits. Key: significance: * and **, P<0.05 and P<0.01,
respectively; B, D, E and G paired t-test and H Wilcoxon signed-rank test.
Figure 5. Proposed mechanism of action of Glo1 inducer formulation. Key: yellow filled
arrows – mechanism of health improvement by; red filled arrows – damaging processes
suppressed. See also (40; 42-44). Abbreviations: KLB, β-klotho; CBP, CREB binding
protein; FGFR1c, fibroblast growth factor receptor 1c; and maf, small maf protein –
accessory proteins for Nrf2 activation.
Xue et al., Improved glycemic control etc, Figure 1
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Materials
Tissue culture materials, medium MCDB-131, L-glutamine and recombinant human
epidermal growth factor were from Invitrogen (Paisley, UK) and fetal bovine serum from
Biosera (Ringmer, UK). Human Glo1 antibody was available from a previous in-house
preparation (55). Dietary bioactive compounds were purchased from Extrasynthese (69727
Genay Cedex, France), LKT Laboratories Inc. (St. Paul, MN 55130, USA) and Sigma (Poole,
UK). [2H3]HESP was from Toronto Research Chemicals (Toronto, Canada). GSH, oxidised
glutathione (GSSG), [13C6]tRES. [glycine-13C2,15N]GSH ( 98% 15N and 99% 13C), β-
glucuronidase from Helix pomatia, β-sulphatase from Helix pomatia, acetoacetate
colorimetric assay kit (cat no. MAK199-1KT) and all other chemicals used in this project
were from Sigma. [13C415N2]GSSG was synthesised in-house from [glycine-13C2,15N]GSH by
oxidation by diamide and purification by anion exchange chromatography (yield 28%), as
described (56). β-Hydroxybutyrate colorimetric assay kit (cat no. ab83390) was from Abcam 
(Cambridge, U.K.). Primary human aortal endothelial cells (HAEC) were purchased from
Lonza (Slough, U.K) and human dermal foreskin BJ fibroblasts at cumulative population
doubling of 22 were purchased from the European Collection of Animal Cell Cultures
(Porton Down, UK). For the HATFF study, tRES was from DSM (Heerlen, Netherlands) and
HESP was supplied by Symrise BioActives GmbH (Hamburg, Germany). Placebo and tRES-
HESP hard gelatin capsules were prepared by Pharmavize (Ghent, Belgium).
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Supplementary Table 1. Safety assessment of trans-resveratrol-hesperetin co-formulation in the HATFF study.
Placebo tRES-HESP
Variable Baseline Post-supplement Baseline Post-supplement
Aspartate aminotransferase (U/L) 20.1 ± 0.9 21.4 ± 1.2 20.9 ± 1.0 20.4 ± 0.9
Alanine aminotransferase (U/L) 18.5 (13.5 – 33.0) 20.0 (15.0 – 30.0) 19.0 (15.0 – 26.5) 18.0 (13.5 – 31.0)
γ-Glutamyl transferase (U/L) 20.0 (12.5 – 41.5) 19.0 (13.5 – 37.5) 26.0 (14.5 – 37.0) 21.0 (13.5 – 38.0)
alkaline phosphatase (U/L) 63.1 ± 2.9 65.7 ± 3.3 66.1 ± 3.1 66.0 ± 3.0
Albumin (g/L) 44.4 ± 0.4 44.6 ± 0.4 44.4 ± 0.5 44.6 ± 0.5
Total protein (g/L) 70.2 ± 0.6 69.3 ± 0.8 69.8 ± 0.7 69.2 ± 0.7
Bilirubin (mg/L) 8.69 ± 0.88 8.59 ± 0.71 8.97 ± 0.99 8.59 ± 0.80
Haemoglobin (mg/L) 137 ± 2 138 ± 2 138 ± 2 137 ± 2
Red blood cells (106 per μL) 4.61 ± 0.07 4.67 ± 0.08 4.66 ± 0.07 4.67 ± 0.07
Mean corpuscular volume (fL/cell) 89.7 ± 0.7 89.7 ± 0.8 90.4 ± 0.7 89.9 ± 0.7
Leukocyte count (109 per L) 5.54 ± 0.23 5.68 ± 0.28 5.38 ± 0.28 5.55 ± 0.25
Thrombocyte no (109 per L) 247 ± 8 244 ± 7 248 ± 10 248 ± 8
Prothrombin time (s) 10.6 ± 0.1 10.6 ± 0.1 10.7 ± 0.1 10.5 ± 0.1
Sodium (mM) 141 ± 1 141 ± 1 141 ± 1 141 ± 1
Potassium (mM) 4.32 ± 0.05 4.30 ± 0.05 4.34 ± 0.04 4.29 ± 0.05
Chloride (mM) 100 ± 1 101 ± 1 101 ± 1 101 ± 1
Phosphate (mM) 1.07 ± 0.02 1.08 ± 0.03 1.10 ± 0.02 1.08 ± 0.02
Data are mean ± SEM or median (lower – upper quartile); n = 29. There was no significant difference in analytes assessed by 2- or 4-group
testing.
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Supplementary Table 2. PBMC gene expression changes in the HATFF study.
A: Baseline and post-supplementation comparisons for placebo and tRES+HESP.
Study
group
Placebo tRES-HESP Δ + tRES-HESP from: 
Baseline† [Post-supplement]‡
Significance P from:
Baseline [Post-supplement]
Freidman
testGene Baseline Post-supplement Baseline Post-supplement
All GLO1 0.392 (0.356 – 0.436) 0.415 (0.375 – 0.463) ---- [0.023 (6%)] ---- [<0.05] ----
HIF1A 2.12 (1.94 – 2.39) 2.00 (1.77 – 2.30) ---- [- 0.12 (- 6%)] ---- [<0.05] ----
IL8 0.197 (0.151-0.562) 0.120 (0.090 - 0.293) ---- [- 0.077 (39%)] ---- [<0.05] ----
PTGS2 0.078 (0.063-0.158) 0.087 (0.064-0.187) 0.084 (0.065-0.132) 0.059 (0.048-0.073) - 0.025 (30%) [0.028 (-32%)] <0.05 [<0.01] <0.05
Highly
over-
weight
FTH1 2.40 (1.82 – 3.71) 1.95 (1.65 – 3.11) ---- [- 0.45 (- 19%)] ---- [<0.05] ----
HIF1A 2.15 (1.93 – 2.61) 1.99 (1.78 – 2.30) ---- [- 0.16 (- 8%)] ---- [<0.05] <0.01
IL8 0.186 (0.149-0.718) 0.094 (0.083 - 0.261) ---- [- 0.092 (- 49%)] ---- [<0.05] <0.05
PTGS2 0.086 (0.062 – 0.200) 0.059 (0.046 – 0.067) ---- [- 0.027 (- 31%)] ---- [<0.01] ----
Obese CCL2 0.049 (0.035–0.056) 0.052 (0.036 – 0.108) 0.051 (0.044-0.076) 0.040 (0.033 – 0.055) -0.012 (-22%) [- 0.012 (- 23%)] <0.05 [<0.05] ----
HIF1A 1.98 (1.82 – 2.62) 1.85 (1.72 – 1.99) ---- [- 0.13 (- 7%)] ---- [<0.05] <0.05
IL8 0.184 (0.096-0.298) 0.181(0.144-0.456) 0.241(0.106-0.904) 0.091(0.084-0.164) - 0.150 (- 62%) ---- <0.05 [<0.05] ----
KEAP1 0.216 (0.173 – 0.259) 0.178 (0.147 – 0.201) ---- [- 0.038 (- 18%)] ---- [<0.05] ----
PTGS2 0.077 (0.062-0.163) 0.083 (0.066-0.156) 0.092 (0.064-0.182) 0.058 (0.041-0.073) - 0.034 (- 37%) [-0.025 (- 30%)] <0.05 [<0.05] ----
TNFA 0.552 (0.436 – 0.735) 0.486 (0.376– 0.612) ---- [-0.066 (- 12%)] ---- [<0.05] ----
29
Supplementary Table 2. PBMC gene expression changes in the HATFF study (cont’d).
B: Change for baseline comparisons.
Change from baseline Significance
Study group Gene Placebo tRES-HESP
All GLO1 - 0.010 (- 0.063 – 0.0155) 0.013 (- 0.028 – 0.079); + 6% <0.05
Highly overweight/obese RAGE 0.048 (- 0.017 - 0.149) - 0.016 (- 0.116 – 0.021); - 37% <0.05
CCL2 0.014 (- 0.007 – 0.040) - 0.008 (- 0.035 – 0.005); - 49% <0.01
Data are median (lower – upper quartile). For obese, highly overweight/obese and all study groups, n = 11, 20 and 29, respectively.
A: tRES-HESP treatment changes, Δ + tRES-HESP. †Absolute and percentage (in parentheses) changes from baseline + tRES-HESP.  ‡ in 
square brackets [ ], absolute and percentage (in parentheses) changes at post-supplement with respect to placebo. Related significance levels are
also given. Baseline values have been omitted for clarity where only post-supplementation changes are significant. Gene expression assessed but
not showing significant change was: AKR1B1, AKR1C1, AKR1C3, CAT, CBR1, CCR2, CD36, G6PD, GCLC, GCLM, GPX1, GPX4, GSR,
GSTA4, GSTP1, HMOX1, IL6, KEAP1, MAFF, MAFG, MAFK, MIF, MLX, MLXIP, NCF1, NFE2L2, NFKB1, NFKBIA, NQO1, PRDX1,
PSMA1, PSMB5, SOD1, SQSTM1, SREBF1, TALDO1, TKT, TXN, TXNIP, TXNRD1.
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Supplementary figures
Figure legends
Supplementary Figure 1. Effect of trans-resveratrol, hesperetin and trans-resveratrol
and hesperetin combined on gene expression in human cells in vitro. A: HAECs. Genes
(top to bottom): GST4A, HMOX1, GCLM, GCLC, GSR and ICAM-1. B: BJ fibroblasts in
primary culture. Genes (top to bottom): GSTP1, HMOX1, NQO1, AKR1C1, CCL2 and
ICAM1. C: HepG2 cells. Genes (top to bottom): NQO1, GCLM, GCLC, LDLR, HK2, and
PFKBP3. Relative mRNA copy number, normalised to control. Cells were washed twice with
ice-cold PBS and total RNA was extracted using RNeasy Mini Kit (Qiagen). Total RNA (600
– 800 ng) was analysed for mRNA copy number of target genes by the NanoString nCounter
method (outsourced to Nanostring, Seattle, USA). Custom codeset of genes including three
reference genes (β-actin, clathrin heavy chain and β-glucuronidase) was designed. Similar 
studies were performed with PBMC RNA extracts from the clinical study. Key for section A,
B and C: left-hand panel, red line, + 5.0 μM tRES; middle panel, blue line, + 5.0 μM HESP; 
and  right-hand panel, green line, + 5.0 μM tRES & HESP. Data are mean ± SD (n = 3).
Significance: *, ** and ***, P<0.05, P<0.01 and P<0.001 with respect to unstimulated control.
Supplementary Figure 2. Urinary excretion of total trans-resveratrol and hesperetin
metabolites in the HATFF clinical study. A: Total tRES metabolites. B: Total HESP
metabolites. Data are median [lower – upper quartile; n = 29] in tRES and HESP equivalents
(mg/24 h). Urine samples were collected in the 24 h immediately prior to the visits to the clinic
before and end of the supplementation periods. Where no analyte was detected, metabolite
excretion was <LOD (0.012 mg/24 h tRES and <0.004 mg/24 h HESP). Analyte retention time
Rt, molecular ion mass, fragment ion mass, cone voltage and collision energy for detection
were: tRES – Rt = 5.0 min, 229.2 Da, 134.8 Da, 36 V and 18 eV; cis-RES – as for tRES
except Rt = 7.2 min; [13C6]tRES - Rt = 5.0 min, 235.2 Da, 134.8 Da, 36 V and 18 eV; HESP -
Rt = 10.0 min, 303.2 Da, 152.9 Da, 34 V and 27 eV; and [2H3]HESP - Rt = 10.0 min, 306.2
Da, 152.9 Da, 34 V and 27 eV. Mass spectrometric detection conditions were: positive ion
multiple reaction monitoring, capillary voltage 3.7 kV, extractor voltage 4 V, electrospray
source and desolvation gas temperatures 120 oC and 350 oC and desolvation and cone
nitrogen gas flows 750 L/h and 200 L/h, respectively. The limit of detection was: tRES, 2
nM, and HESP – 10 nM. The chromatography column was BEH C18, 1.7 µm particle size
100 x 2.1 mm column fitted with a 5 x 2.1 mm pre-column at 30 oC (Waters, UK). Mobile
phases were: A, 25% acetonitrile, 0.1% trifluoroacetic acid (TFA) in water; B, 0.1% TFA in
MeCN; the flow rate was 0.2 ml/min. The elution profile was 100% A and a linear gradient
of 0 – 37.5% B over 10 min and isocratic 27.5% B from 10 – 15 min. No cis-RES nor
eriodictyol (demethylated HESP) was detected in study samples.
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